The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...